CANY
IMGN

Caxton Associates (New York)’s Immunogen Inc IMGN Stock Holding History

Caxton Associates (New York)’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,839
Closed -$299K – 566
2023
Q3 		$299K Buy
+18,839
New +$313K 0.04% 308

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Caxton Associates (New York)'s IMGN Position: Q4 2023 in Review

Caxton Associates (New York) sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 18,839 shares — an estimated $299K sold.

Caxton Associates (New York) first reported a position in IMGN in Q3 2023 and held it in 1 quarter. The position peaked at $299K in Q3 2023. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • Caxton Associates (New York) reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,839 Immunogen Inc shares in Q4 2023, an estimated $299K.
  • Caxton Associates (New York) first reported a position in Immunogen Inc in Q3 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Immunogen Inc position peaked at $299K in Q3 2023.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.